JP2021519786A5 - - Google Patents
Info
- Publication number
- JP2021519786A5 JP2021519786A5 JP2020552869A JP2020552869A JP2021519786A5 JP 2021519786 A5 JP2021519786 A5 JP 2021519786A5 JP 2020552869 A JP2020552869 A JP 2020552869A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2021519786 A5 JP2021519786 A5 JP 2021519786A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- hydrogen
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650922P | 2018-03-30 | 2018-03-30 | |
| US62/650,922 | 2018-03-30 | ||
| PCT/US2019/024612 WO2019191451A1 (en) | 2018-03-30 | 2019-03-28 | Thienopyrimidinone compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021519786A JP2021519786A (ja) | 2021-08-12 |
| JP2021519786A5 true JP2021519786A5 (enExample) | 2022-04-04 |
Family
ID=66102328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552869A Pending JP2021519786A (ja) | 2018-03-30 | 2019-03-28 | チエノピリミジノン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10584133B2 (enExample) |
| EP (1) | EP3774815A1 (enExample) |
| JP (1) | JP2021519786A (enExample) |
| CN (1) | CN112313236A (enExample) |
| AU (1) | AU2019243186A1 (enExample) |
| CA (1) | CA3094988A1 (enExample) |
| TW (1) | TW202003524A (enExample) |
| WO (1) | WO2019191451A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021105335A1 (en) * | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| KR20230005210A (ko) * | 2020-04-08 | 2023-01-09 | 레믹스 테라퓨틱스 인크. | 스플라이싱을 조절하기 위한 화합물 및 방법 |
| US20240025863A1 (en) | 2020-09-16 | 2024-01-25 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| CN117203196A (zh) | 2020-12-14 | 2023-12-08 | 拜欧斯瑞克斯公司 | Pde4降解剂、药物组合物和治疗应用 |
| AU2022207648A1 (en) | 2021-01-13 | 2023-07-27 | Monte Rosa Therapeutics Ag | Isoindolinone compounds |
| WO2022255890A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| JP2024527628A (ja) * | 2021-07-19 | 2024-07-25 | メッドシャイン ディスカバリー インコーポレイテッド | ヘテロアリール－３－ピペリジンジオン化合物その使用 |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334596A (en) | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| MXPA04008797A (es) | 2002-03-13 | 2004-11-26 | Janssen Pharmaceutica Nv | Inhibidores de histona desacetilasa. |
| WO2005030705A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US20050176738A1 (en) | 2003-11-07 | 2005-08-11 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| PH12013501837A1 (en) * | 2011-03-11 | 2013-11-18 | Celgene Corp | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2,6-dione in treatment of immune-related and inflammatory diseases |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| KR101446680B1 (ko) | 2013-02-08 | 2014-10-07 | 한국과학기술연구원 | ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체 |
| WO2014172436A1 (en) * | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| JP2018535958A (ja) | 2015-10-27 | 2018-12-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用 |
| KR20180095094A (ko) * | 2016-01-08 | 2018-08-24 | 셀진 코포레이션 | 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도 |
| BR112018068906A2 (pt) * | 2016-03-16 | 2019-01-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo |
| US10040804B2 (en) * | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10406165B2 (en) * | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
-
2019
- 2019-03-28 CA CA3094988A patent/CA3094988A1/en not_active Abandoned
- 2019-03-28 WO PCT/US2019/024612 patent/WO2019191451A1/en not_active Ceased
- 2019-03-28 CN CN201980036091.5A patent/CN112313236A/zh active Pending
- 2019-03-28 EP EP19716755.4A patent/EP3774815A1/en not_active Withdrawn
- 2019-03-28 JP JP2020552869A patent/JP2021519786A/ja active Pending
- 2019-03-28 US US16/368,409 patent/US10584133B2/en active Active
- 2019-03-28 AU AU2019243186A patent/AU2019243186A1/en not_active Abandoned
- 2019-03-29 TW TW108111421A patent/TW202003524A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519786A5 (enExample) | ||
| US12351582B2 (en) | Aurora kinase inhibitors and uses thereof | |
| JP2018138577A5 (enExample) | ||
| JP2023508055A5 (enExample) | ||
| JP2008525530A5 (enExample) | ||
| JP2022520448A5 (enExample) | ||
| US9309224B2 (en) | N-acyl-N′-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| JP2023123854A5 (enExample) | ||
| JP2008528467A5 (enExample) | ||
| JP2016523973A5 (enExample) | ||
| JP2015533177A5 (enExample) | ||
| JP2022520811A5 (enExample) | ||
| JP2021529812A5 (enExample) | ||
| RU2011125376A (ru) | Способ получения соединений дигидроинденамида, фармацевтические композиции, содержащие данные соединения, и их применение в качестве ингибитора протеинкиназы | |
| JP2022526266A5 (enExample) | ||
| JP2013531055A5 (enExample) | ||
| RU2010145463A (ru) | Производные замещенного 2-фенилпиридина | |
| JP2023533203A5 (enExample) | ||
| JP2020506895A5 (enExample) | ||
| JP2019505595A5 (enExample) | ||
| CA2565852C (en) | 3- or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| RU2012124811A (ru) | СПОСОБ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНЫХ НАРУШЕНИЙ И ДРУГИХ ПАТОЛОГИЧЕСКИХ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ АКТИВНОСТЬЮ КИНАЗ Bcr-Abl, c-Kit, DDR1, DDR2, ИЛИ PDGF-R | |
| JP2014520108A5 (enExample) | ||
| JP2023531495A5 (enExample) | ||
| CA2617991A1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof |